These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 29672891)

  • 21. Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapy.
    Grebely J; Dore GJ; Alami NN; Conway B; Dillon JF; Gschwantler M; Felizarta F; Hézode C; Tomasiewicz K; Fredrick LM; Dumas EO; Mensa FJ
    Int J Drug Policy; 2019 Apr; 66():73-79. PubMed ID: 30735896
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Safety of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II/III Trials.
    Heo J; Kim YJ; Lee JW; Kim JH; Lim YS; Han KH; Jeong SH; Cho M; Yoon KT; Bae SH; Crown ED; Fredrick LM; Alami NN; Asatryan A; Kim DH; Paik SW; Lee YJ
    Gut Liver; 2021 Nov; 15(6):895-903. PubMed ID: 34053916
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of glecaprevir and pibrentasvir treatment for 8 or 12 weeks in patients with recurrent hepatitis C after liver transplantation: a Japanese multicenter experience.
    Ueda Y; Kobayashi T; Ikegami T; Miuma S; Mizuno S; Akamatsu N; Takaki A; Ishigami M; Takatsuki M; Sugawara Y; Maehara Y; Uemoto S; Seno H
    J Gastroenterol; 2019 Jul; 54(7):660-666. PubMed ID: 30806783
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-Life Effectiveness and Safety of Glecaprevir/Pibrentasvir for Korean Patients with Chronic Hepatitis C at a Single Institution.
    Park YJ; Woo HY; Heo J; Park SG; Hong YM; Yoon KT; Kim DU; Kim GH; Kim HH; Song GA; Cho M
    Gut Liver; 2021 May; 15(3):440-450. PubMed ID: 32839365
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study.
    Cornberg M; Ahumada A; Aghemo A; Andreoni M; Bhagat A; Butrymowicz I; Carmiel M; Chodick G; Conway B; Song Y; Gasbarrini A; Hüppe D; Plaza FJ; Lampertico P; Alonso MLM; Myles L; Persico M; Ramji A; Sarrazin C; Villa E; Weil C; Otano JIU;
    Adv Ther; 2022 Jul; 39(7):3146-3158. PubMed ID: 35543964
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis.
    Asselah T; Kowdley KV; Zadeikis N; Wang S; Hassanein T; Horsmans Y; Colombo M; Calinas F; Aguilar H; de Ledinghen V; Mantry PS; Hezode C; Marinho RT; Agarwal K; Nevens F; Elkhashab M; Kort J; Liu R; Ng TI; Krishnan P; Lin CW; Mensa FJ
    Clin Gastroenterol Hepatol; 2018 Mar; 16(3):417-426. PubMed ID: 28951228
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and Pharmacokinetics of Glecaprevir and Pibrentasvir With Concurrent Use of Acid-Reducing Agents in Patients With Chronic HCV Infection.
    Flamm S; Reddy KR; Zadeikis N; Hassanein T; Bacon BR; Maieron A; Zeuzem S; Bourliere M; Calleja JL; Kosloski MP; Oberoi RK; Lin CW; Yu Y; Lovell S; Semizarov D; Mensa FJ
    Clin Gastroenterol Hepatol; 2019 Feb; 17(3):527-535.e6. PubMed ID: 30012435
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5/6: An integrated analysis of phase 2/3 studies.
    Yao BB; Fredrick LM; Schnell G; Kowdley KV; Kwo PY; Poordad F; Nguyen K; Lee SS; George C; Wong F; Gane E; Abergel A; Spearman CW; Nguyen T; Hung Le M; Pham TT; Mensa F; Asselah T
    Liver Int; 2020 Oct; 40(10):2385-2393. PubMed ID: 32445613
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sofosbuvir, Glecaprevir, Pibrentasvir, and Ribavirin as a Rescue Therapy in Difficult-to-Treat HCV Patients.
    Meszaros M; Truchi R; Ouzan D; Tran A; Bourlière M; Pageaux GP
    Hepatology; 2021 Oct; 74(4):2304-2306. PubMed ID: 34008214
    [No Abstract]   [Full Text] [Related]  

  • 30. Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial.
    Asselah T; Lee SS; Yao BB; Nguyen T; Wong F; Mahomed A; Lim SG; Abergel A; Sasadeusz J; Gane E; Zadeikis N; Schnell G; Zhang Z; Porcalla A; Mensa FJ; Nguyen K
    Lancet Gastroenterol Hepatol; 2019 Jan; 4(1):45-51. PubMed ID: 30393106
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis.
    Puoti M; Foster GR; Wang S; Mutimer D; Gane E; Moreno C; Chang TT; Lee SS; Marinho R; Dufour JF; Pol S; Hezode C; Gordon SC; Strasser SI; Thuluvath PJ; Zhang Z; Lovell S; Pilot-Matias T; Mensa FJ
    J Hepatol; 2018 Aug; 69(2):293-300. PubMed ID: 29551706
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study.
    Rockstroh JK; Lacombe K; Viani RM; Orkin C; Wyles D; Luetkemeyer AF; Soto-Malave R; Flisiak R; Bhagani S; Sherman KE; Shimonova T; Ruane P; Sasadeusz J; Slim J; Zhang Z; Samanta S; Ng TI; Gulati A; Kosloski MP; Shulman NS; Trinh R; Sulkowski M
    Clin Infect Dis; 2018 Sep; 67(7):1010-1017. PubMed ID: 29566246
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of Glecaprevir/Pibrentasvir and Sofosbuvir/Ledipasvir in Patients with Hepatitis C Virus Genotype 1 and 2 in South Korea.
    Shin HD; Song IH; Lee SH; Kim HS; Lee TH; Eun HS; Kim SH; Lee BS; Chae HB; Kim SH; Song MJ; Ko SY; Kim SB
    Korean J Gastroenterol; 2024 Mar; 83(3):111-118. PubMed ID: 38522854
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of glecaprevir and pibrentasvir in Saudi patients with chronic hepatitis C virus infection at a major tertiary hospital.
    Ruwayni AA; AlObary EE; Alyahya KM
    Saudi Med J; 2024 Jan; 45(1):34-39. PubMed ID: 38220241
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis.
    Lampertico P; Carrión JA; Curry M; Turnes J; Cornberg M; Negro F; Brown A; Persico M; Wick N; Porcalla A; Pangerl A; Crown E; Larsen L; Yu Y; Wedemeyer H
    J Hepatol; 2020 Jun; 72(6):1112-1121. PubMed ID: 32061651
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts.
    Forns X; Feld JJ; Dylla DE; Pol S; Chayama K; Hou J; Heo J; Lampertico P; Brown A; Bondin M; Tatsch F; Burroughs M; Marcinak J; Zhang Z; Emmett A; Gordon SC; Jacobson IM
    Adv Ther; 2021 Jun; 38(6):3409-3426. PubMed ID: 34021887
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection.
    Naganuma A; Chayama K; Notsumata K; Gane E; Foster GR; Wyles D; Kwo P; Crown E; Bhagat A; Mensa FJ; Otani T; Larsen L; Burroughs M; Kumada H
    J Gastroenterol; 2019 Aug; 54(8):752-761. PubMed ID: 30868245
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial.
    Forns X; Lee SS; Valdes J; Lens S; Ghalib R; Aguilar H; Felizarta F; Hassanein T; Hinrichsen H; Rincon D; Morillas R; Zeuzem S; Horsmans Y; Nelson DR; Yu Y; Krishnan P; Lin CW; Kort JJ; Mensa FJ
    Lancet Infect Dis; 2017 Oct; 17(10):1062-1068. PubMed ID: 28818546
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection.
    Lawitz E; Flisiak R; Abunimeh M; Sise ME; Park JY; Kaskas M; Bruchfeld A; Wörns MA; Aglitti A; Zamor PJ; Xue Z; Schnell G; Jalundhwala YJ; Porcalla A; Mensa FJ; Persico M
    Liver Int; 2020 May; 40(5):1032-1041. PubMed ID: 31821716
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection.
    Ng TI; Pilot-Matias T; Tripathi R; Schnell G; Krishnan P; Reisch T; Beyer J; Dekhtyar T; Irvin M; Lu L; Asatryan A; Campbell A; Yao B; Lovell S; Mensa F; Lawitz EJ; Kort J; Collins C
    Viruses; 2018 Aug; 10(9):. PubMed ID: 30154359
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.